Skip to main content

Table 14 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the Barthel Index, for the subgroup in Ireland

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

  EQ-5D-3L at 6 months (mean) EQ-5D-3L at 12 months (mean) Difference between 12 and 6 months EQ-5D-3L (95% CI) Effect size (Cohen’s D)a n % reporting 3L score increase
Barthel Index
Improved 0.71 0.87 0.15 (− 0.05 to 0.36) 0.74 11 45
No change 0.90 0.84 − 0.05 (0.18 to 0.06) − 0.25 29 24
Worsened 0.57 0.57 0.00 (− 0.29 to 0.29) 0.00 8 38
  EQ-5D-5L at 6 months (mean) EQ-5D-5L at 12 months (mean) Difference between 12 and 6 months EQ-5D-5L (95% CI) Effect size (Cohen’s D) n % reporting 5L score increase
Barthel Index       
 Improved 0.73 0.86 0.12 (− 0.01 to 0.26) 0.61 11 55
 No change 0.89 0.83 − 0.05 (− 0.16 to 0.05) − 0.25 29 31
 Worsened 0.69 0.59 − 0.09 (− 0.30 to 0.10) − 0.35 8 38
  1. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large